Colon Cancer

Colon cancer is rated under 38 CFR § 4.114, diagnostic code 7343, the code for malignant neoplasms of the digestive system, exclusive of skin growths. Unlike most musculoskeletal codes, where you read one set of tiers and find your number, DC 7343 has two distinct phases. During active malignancy and treatment, the rating is a flat 100 percent. After treatment ends, that 100 percent does not stay forever. The condition gets re-rated on its residuals.

That two-phase structure is the whole story of a colon cancer claim, and it is where most of the disputes I see in the dataset begin. The 100 percent phase is the simpler half. As long as there is active cancer or ongoing surgical, chemotherapy, radiation, or other antineoplastic treatment, the rating sits at total. The harder half is the transition. VA is required to schedule a mandatory examination six months after the last treatment ends, and based on that exam the rating either continues or shifts to a residuals evaluation under whatever digestive code best captures what is left behind.

This page walks through both phases under DC 7343, the six-month mandatory exam and what it has to find, the § 3.105(e) procedure that protects you when VA tries to reduce a rating, the residual codes that a post-treatment colon cancer rating usually lands under, the Camp Lejeune and toxic-exposure nexus pathways, and the secondary conditions that flow from treatment. The Camp Lejeune association matters more here than in a typical orthopedic claim, because the exposure question can decide whether the cancer is service-connected at all.

TL;DR

• Colon cancer is rated under 38 CFR § 4.114, DC 7343 (malignant neoplasm of the digestive system, exclusive of skin growths).
• The rating runs in two phases. A 100 percent evaluation applies during active malignancy and treatment.
• The 100 percent continues through treatment, and a mandatory VA examination is conducted six months after the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure.
• If there is no local recurrence or metastasis at that exam, the condition is then rated on its residuals under the appropriate digestive code.
• Residuals commonly rate under post-resection digestive criteria, impairment of sphincter control (DC 7332), or the rules for an ostomy.
• Any reduction from 100 percent follows the procedural protections in 38 CFR § 3.105(e).
• Colorectal cancer is associated with Camp Lejeune contaminated-water exposure and is considered in some toxic-exposure contexts. The exposure and the pathology both have to be documented.
• Treatment residuals open secondary chains under § 3.310: bowel dysfunction, ostomy care, anemia, chemotherapy-induced peripheral neuropathy, and fatigue.
• In Claim Raven's analysis of 526 colon cancer cases, 26.2% were granted, 42.0% were remanded, and 20.7% were denied. Of the 394 cases with a C&P adequacy determination, 72.6% had the exam flagged as inadequate.

DC 7343 and the Two-Phase Rating Structure

DC 7343 sits in the digestive system section of 38 CFR § 4.114 and covers malignant neoplasms of the digestive system other than skin growths. Colon, rectal, and other colorectal cancers fall under it. The code does not hand you a table of percentages tied to symptom severity the way a range-of-motion code does. Instead, it sets a process.

During active disease, the regulation assigns a 100 percent evaluation. That total rating holds while the cancer is active and while you are undergoing any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. The point of the 100 percent phase is that active cancer and its treatment are presumed totally disabling. You do not have to prove specific symptoms during this window. The diagnosis and the active treatment carry the rating.

The second phase begins after treatment ends. The 100 percent does not automatically continue. The regulation provides that a mandatory VA examination follows the cessation of treatment, and the rating going forward depends on what that exam finds. If there is no local recurrence or metastasis, the cancer is rated on its residuals. If there is recurrence or metastasis, the 100 percent continues, because there is again active malignant disease.

The reason this structure trips people up is that it looks like a downgrade waiting to happen. It is not a discretionary reduction. It is a structural feature of how VA rates cancers that respond to treatment. The protection is not in stopping the re-rating, it is in making sure the re-rating is done correctly, on accurate residuals, and with the procedural safeguards that § 3.105(e) requires. That is where a colon cancer claim is won or lost on the back end.

The Six-Month Mandatory Exam

The hinge of the entire claim is the mandatory examination. The regulation directs that a VA examination be conducted six months following the cessation of any surgical, X-ray, antineoplastic chemotherapy, or other therapeutic procedure. The exam exists to answer one question first: is there local recurrence or metastasis? Everything else follows from that answer.

If the exam finds active recurrence or metastatic disease, the analysis is straightforward. There is again active malignancy, and the 100 percent evaluation continues. The two-phase clock effectively resets.

If the exam finds no recurrence and no metastasis, the rating shifts to a residuals evaluation. This is the moment the examiner's documentation matters most, because the residuals rating is built entirely from what the exam records. A thorough exam that captures bowel frequency, sphincter control, the presence and management of an ostomy, weight loss, anemia, and the functional cost of treatment gives the rater the evidence to assign an accurate residuals rating. A thin exam that records "status post colon resection, no recurrence" and stops there gives the rater almost nothing, and the residuals rating that results tends to be lower than the actual disability.

Timing is its own problem. The exam is supposed to happen six months after treatment ends, but "treatment ends" is not always a clean date. Adjuvant chemotherapy, follow-up surgical procedures, and ongoing surveillance can blur the line. When the exam is scheduled prematurely, before treatment has actually ceased, or when it is scheduled but the examiner fails to address recurrence and residuals adequately, that is the kind of defect the Board sends back. Across the colon cancer cases in the dataset, the high rate of inadequate exams and remands tracks with exactly this dynamic: the rating turns on one exam, and that exam often does not do the job the regulation assigns it.

Reductions and the § 3.105(e) Protection

A move from 100 percent to a residuals rating is a reduction, and a reduction in a running rating is not something VA can do informally. The procedure lives in 38 CFR § 3.105(e). When a reduction in evaluation would result in a lower disability payment, VA has to issue a rating proposing the reduction, set out the reasons, and give you notice and an opportunity to respond, including the right to a predetermination hearing, before the reduction takes effect.

This matters because the residuals phase of DC 7343 is the most common place a colon cancer rating drops. If VA reduces the rating without following the § 3.105(e) procedure, the reduction is procedurally defective and can be challenged on that basis alone, separate from any argument about the underlying severity of the residuals. The Board has set aside reductions for failure to follow the predetermination procedure even where the medical picture might have supported some reduction.

There is a substantive layer too. A reduction generally has to be supported by an examination as full and complete as the one that established the higher rating, and the record has to show actual improvement in the disability under the ordinary conditions of life, not just a better day in the clinic. For a cancer that has been successfully treated, "improvement" is real in the sense that the active disease is gone, but the residuals are a separate question, and they have to be rated on their own merits. If your treatment left you with significant bowel dysfunction, an ostomy, or treatment-induced conditions, the residuals rating should reflect that, and § 3.105(e) gives you the procedural footing to make sure it does.

What the Residuals Actually Rate Under

Once the cancer is in remission and being rated on residuals, the rating moves to whatever digestive code best captures what treatment left behind. There is no single answer, because colon cancer treatment produces different residuals in different people. A few patterns recur.

Post-resection digestive residuals. Most colon cancer treatment involves removing part of the colon. The functional residuals of that resection, altered bowel function, frequency, diarrhea, malabsorption, and weight loss, get rated under the digestive criteria in § 4.114 that fit the symptom picture. The severity of bowel impairment drives the number.

Impairment of sphincter control, DC 7332. When treatment affects rectal and anal sphincter control, the residual is rated under DC 7332. This code rates impairment of sphincter control of the rectum and anus, scaling with the degree of leakage and loss of control, from healed or slight without leakage up through extensive leakage and fairly frequent involuntary bowel movements, and to complete loss of sphincter control at the top tier. For a low rectal cancer or a resection near the sphincter, this is often the controlling residual.

Ostomy. When the surgery results in a colostomy, the rating follows the rules for an ostomy under § 4.114. A permanent colostomy carries its own evaluation that recognizes the burden of ostomy care independent of how well the underlying disease has resolved. The presence of a stoma, whether it is permanent or temporary, and the management burden all factor in.

The right residual code is a medical and factual question, and the brief honest answer is that it depends on the surgery and the symptoms. Where exact tier percentages turn on findings I cannot read from the regulatory structure alone, the controlling rule is that VA rates the residual under the digestive code that produces the most accurate picture of the actual impairment, and pyramiding under § 4.14 prevents rating the same functional loss twice under two codes. The job on the residuals exam is to document each distinct functional loss so the rater can pick the right code and tier.

Camp Lejeune and Toxic-Exposure Nexus Pathways

The service-connection question for colon cancer often turns on exposure, and the most developed exposure pathway is Camp Lejeune. Veterans, reservists, and guardsmen stationed at Marine Corps Base Camp Lejeune were exposed to contaminated drinking water, and colorectal cancer is among the conditions associated with that exposure. For qualifying Camp Lejeune service, the connection between the contaminated water and certain conditions has been recognized in VA's framework, which changes the evidentiary picture compared to an ordinary direct-service-connection claim.

The practical point is that the exposure and the pathology both have to be documented. Service records or other evidence have to establish the qualifying presence at Camp Lejeune during the relevant period. The pathology has to establish that the diagnosis is colorectal cancer rather than a different malignancy. When those two pieces are in the file and aligned, the nexus argument is far stronger than a generic theory of in-service causation. When either piece is missing or vague, the claim stalls.

Colorectal cancer is also considered in some broader toxic-exposure contexts. Veterans with documented exposure to other contaminants or hazardous environments during service may have a toxic-exposure theory available, and the recent expansion of toxic-exposure recognition has widened the routes by which VA considers these claims. I want to be precise here rather than overstate it: the specific recognized pathway with the cleanest evidentiary path for colorectal cancer is Camp Lejeune, and other toxic-exposure theories depend heavily on documenting the specific exposure and a medically sound link to the diagnosis. Do not assume any exposure automatically connects to a colorectal cancer diagnosis. Build the exposure record, get the pathology in writing, and where the link is not presumptive, get a medical nexus opinion that explains the mechanism.

Secondary Conditions From Treatment

Colon cancer treatment is aggressive, and the treatment itself produces conditions that are separately ratable under 38 CFR § 3.310, which allows secondary service connection for conditions caused or aggravated by a service-connected disability. Once the cancer is service-connected, the downstream conditions from surgery, chemotherapy, and radiation are fair game.

Bowel dysfunction. Beyond what gets folded into the primary residuals rating, persistent bowel dysfunction can be a distinct and significant disability. Chronic diarrhea, urgency, incontinence, and malabsorption flow from resection and radiation.

Ostomy care. A colostomy is both a residual of the primary disease and an ongoing care burden. Where the ostomy is the residual being rated under the primary code, the rating already accounts for it, but the surrounding complications, skin breakdown, hernias at the stoma site, and management failures, can add to the picture.

Anemia. Chemotherapy and the cancer itself can produce anemia, which is rated under the hematologic criteria and can be a separate compensable disability when it persists.

Chemotherapy-induced peripheral neuropathy. Oxaliplatin and other agents commonly used in colorectal cancer chemotherapy are well known for causing peripheral neuropathy, often in the hands and feet. This can persist long after treatment ends and is independently ratable under the neurological codes. See peripheral neuropathy for how that condition rates on its own.

Fatigue. Persistent fatigue after cancer treatment is real and can be debilitating, though it is one of the harder residuals to rate because it has to be tied to a ratable mechanism rather than treated as a freestanding symptom.

For any of these, the secondary opinion has to do the same work a knee-to-back opinion does: identify the mechanism, address the time course, and connect the secondary condition to the service-connected cancer or its treatment. A bare assertion that the neuropathy is "due to chemo" is weaker than an opinion that names the agent, the typical neurotoxic profile, and the temporal pattern.

C&P Exam Mechanics: What the Examiner Has to Capture

The residuals exam is the rating engine for the post-treatment phase, and it has to do two jobs at once. First, it has to confirm whether there is local recurrence or metastasis, because that determines whether the 100 percent continues at all. Second, if there is no recurrence, it has to document the residuals in enough detail for the rater to pick the right digestive code and tier.

A complete residuals exam should record:

• Recurrence and metastasis status, with the imaging, colonoscopy, or oncology records that support it
• The surgical history, including the extent of resection and whether a colostomy or ileostomy was created, and whether it is temporary or permanent
• Bowel function: frequency, consistency, urgency, incontinence episodes, and use of pads or appliances
• Sphincter control findings relevant to DC 7332, including the degree and frequency of any leakage
• Weight history and any malabsorption or nutritional impairment
• Anemia and other hematologic effects of treatment
• Peripheral neuropathy from chemotherapy, with the distribution and severity
• Fatigue and functional limitation tied to the cancer or its treatment

When those components are in the report, the residuals rating reflects the actual disability. When the exam is sparse, the rating defaults low. The dataset bears this out: of the 394 colon cancer cases with a C&P adequacy determination, 72.6 percent had the exam flagged as inadequate, which is a strikingly high share and consistent with a code whose entire residuals phase depends on an exam many examiners treat as a simple "no recurrence" check.

Common Evidence Gaps in Colon Cancer Claims

A few patterns I see across BVA decisions involving colon cancer.

The residuals exam treats "no recurrence" as the whole job. The most common gap is an exam that confirms the cancer is in remission and stops. It records no recurrence and no metastasis, which justifies moving off the 100 percent, but it never documents the bowel dysfunction, sphincter impairment, ostomy burden, or treatment residuals that should drive the residuals rating. The result is a reduction to a residuals number that understates the actual disability.

The reduction skips the § 3.105(e) procedure. When VA moves from 100 percent to a residuals rating without the proposed-reduction notice and predetermination opportunity that § 3.105(e) requires, the reduction is procedurally defective. Veterans who do not know the procedure exists often do not raise it, and the defective reduction stands until someone challenges it.

The exposure record is incomplete. For Camp Lejeune and other toxic-exposure theories, the claim needs both the documented qualifying service or exposure and the pathology confirming colorectal cancer. When the service records do not clearly establish the qualifying Camp Lejeune presence, or when the pathology is vague about the cancer type, the nexus argument weakens even though the underlying facts may support it.

Treatment secondaries never get claimed. Chemotherapy-induced peripheral neuropathy, persistent anemia, and ostomy complications are separately ratable, but they often go unclaimed because the focus stays on the cancer itself. The secondary conditions under § 3.310 can add meaningfully to a combined rating and frequently get left out.

Timing of the mandatory exam is wrong. When the six-month exam is scheduled before treatment has actually ended, or before the residuals have stabilized, the resulting rating is built on a premature snapshot. That is a frequent basis for remand.

I do not know the precise share of colon cancer claims that carry one or more of these gaps. What I can say from Claim Raven's analysis of 526 colon cancer cases is that remands ran at 42.0 percent, the single largest outcome category, grants at 26.2 percent, and denials at 20.7 percent, and that of the 394 cases with a C&P adequacy determination, 72.6 percent had the exam flagged as inadequate. That pattern is consistent with the evidence-gap dynamics in this post. The Board is sending colon cancer cases back for further development more often than it is granting or denying them outright, and the inadequate-exam rate points squarely at the residuals exam as the recurring weak link.

Bottom Line

Colon cancer at the VA is a two-phase rating, and understanding the two phases is most of the battle. During active disease and treatment, the rating under 38 CFR § 4.114, DC 7343, is a flat 100 percent, and you do not have to prove symptoms to hold it. After treatment ends, a mandatory examination at the six-month mark decides what comes next: if there is recurrence or metastasis the 100 percent continues, and if there is not, the rating shifts to residuals under the digestive code that best fits what treatment left behind, often post-resection bowel impairment, sphincter impairment under DC 7332, or an ostomy. Any reduction off the 100 percent has to follow the § 3.105(e) procedure, which is a real protection and a frequent point of error. The claims that come out right have an exposure record that ties the cancer to qualifying service, a residuals exam that documents the full functional cost rather than just confirming remission, and the treatment secondaries, neuropathy, anemia, ostomy complications, and fatigue, claimed and rated on their own. Same diagnosis, different paper trail, different rating.

Related Conditions

Colon cancer claims share rating logic and proof issues with other malignancy and digestive pages. See prostate cancer and lung cancer for the same two-phase active-disease-then-residuals structure that runs across VA cancer codes, including the mandatory post-treatment exam and the § 3.105(e) reduction protections. On the digestive side, ulcerative colitis and diverticulitis cover bowel-impairment rating criteria that overlap with the residuals analysis here. Veterans dealing with treatment residuals should also review the secondary conditions tool before assuming the cancer rating alone tells the whole story.

Methodology and Limitations

• Data source: Rating criteria from 38 CFR § 4.114, DC 7343 (malignant neoplasm of the digestive system, exclusive of skin growths), and the residual digestive codes, including impairment of sphincter control under DC 7332 and the ostomy rules. Reduction procedure from 38 CFR § 3.105(e). Pyramiding from § 4.14. Secondary service connection from § 3.310, including aggravation under Allen v. Brown. Camp Lejeune contaminated-water association from VA's toxic-exposure framework.
• Sample size: Patterns in this post are drawn from Claim Raven's analysis of 101,518 condition records drawn from the analyzed subset of Claim Raven's 501,000+ Board-decision library, including 526 colon cancer cases. Within that subset, outcomes ran 26.2% granted, 42.0% remanded, and 20.7% denied. Of the 394 cases with a C&P adequacy determination, 72.6% had the examination flagged as inadequate. The dataset captures overall outcome rather than a per-residual-code breakdown.
• Classification approach: Diagnostic code and procedure definitions drawn from the regulatory text. The two-phase structure and the six-month mandatory exam follow DC 7343 and the general rating note for malignant neoplasms. Reduction analysis follows § 3.105(e). Exposure analysis follows the recognized Camp Lejeune association.
• Limitations:
• The exact residuals rating after treatment depends on the surgery and the symptom picture and is a medical and factual question. Where I describe residual codes qualitatively rather than quoting exact tier percentages, that is deliberate: the controlling number turns on findings the regulatory structure alone does not fix.
• Camp Lejeune and toxic-exposure recognition have specific service-and-exposure requirements. Not every exposure connects to a colorectal cancer diagnosis automatically, and non-presumptive theories require a medical nexus opinion.
• Selection bias: BVA-level patterns reflect cases that appealed. Most colon cancer claims resolve at the RO level and are not in any BVA dataset.
• Compensation amounts adjust annually with COLA and are not quoted here.
• These observations reflect patterns from the regulatory text and BVA decisions. They are not predictions of individual outcomes.